---
title: "Hepion Pharmaceuticals, Inc. (HEPA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HEPA.US.md"
symbol: "HEPA.US"
name: "Hepion Pharmaceuticals, Inc."
industry: "制藥"
---

# Hepion Pharmaceuticals, Inc. (HEPA.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [epionpharma.com](https://epionpharma.com) |

## Company Profile

Hepion Pharmaceuticals, Inc.是一家生物制藥公司，專注于在美國開發肝細胞癌（HCC）和其他慢性肝病的治療。該公司開發了 Rencofilstat，這是一種治療藥物候選者，能夠結合並抑制一種特定類別的異構酶——環孢素酶的功能，這種酶調節蛋白質折疊。此外，Rencofilstat 的臨床前實驗顯示出肝纖維化、肝炎、肝腫瘤負擔以及 HBV、HCV、HDV 和 HIV-1 的滴度均有所降低。該公司之前被稱為 ContraVir Pharmaceuticals, Inc.，后來更名為 Hepion Pharmaceuticals, Inc

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.05 | 63/257 | - | - | - |
| PB | 0.29 | 12/257 | 0.44 | 0.37 | 0.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/HEPA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HEPA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HEPA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.